WSJ: Pfizer looks at restructuring R&D, new cuts

The Wall Street Journal reports that Pfizer's new CEO, Jeffrey Kindler (photo), is preparing to announce new job cuts on Monday, as he steps up the company's restructuring efforts. As part of the new approach, Kindler is evidently looking at containing R&D expenses while making cuts in marketing and administration. At the same time, company insiders tell the JoIurnal that Kindler is considering reorganizing scientists into disease groups, in order to hold the company's scientists accountable for their results.

- here's the article from The Wall Street Journal (sub. req.)

Related Articles:
What's next for Pfizer? Report
Pfizer to axe 2,200 sales jobs in realignment. Report
Pfizer's Kindler leaves analysts feeling flat. Report
CEO McKinnell gets the boot as Pfizer struggles. Report

Suggested Articles

The Japanese drugmaker pulled the trigger on the deal after getting a look at phase 1 data on the glutenase TAK-062.

Vanda Pharmaceuticals is hoping to try again with an amended trial after its experimental skin drug tradipitant failed a phase 3 test.

Immuno-oncology biotech Iovance Biotherapeutics’ shares rocketed up by nearly 40% Tuesday on buyout chatter.